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Carbon nanotubes (CNTs) have promised a range of applications in biomedicine. Although influenced by the dispersants used, CNTs are
recognized by the innate immune system, predominantly by the classical pathway of the complement system. Here, we confirm that complement
activation by the CNT used continues up to C3 and C5, indicating that the entire complement system is activated including the formation of
membrane-attack complexes. Using recombinant forms of the globular regions of human C1q (gC1q) as inhibitors of CNT-mediated classical
pathway activation, we show that C1q, the first recognition subcomponent of the classical pathway, binds CNTs via the gC1q domain. Complement
opsonisation of CNTs significantly enhances their uptake byU937 cells, with concomitant downregulation of pro-inflammatory cytokines and up-
regulation of anti-inflammatory cytokines in both U937 cells and human monocytes. We propose that CNT-mediated complement activation may
cause recruitment of cellular infiltration, followed by phagocytosis without inducing a pro-inflammatory immune response.
From the Clinical Editor: This study highlights the importance of the complement system in response to carbon nanontube administration,
suggesting that the ensuing complement activation may cause recruitment of cellular infiltration, followed by phagocytosis without inducing
a pro-inflammatory immune response.
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nanotubes (CNTs) make them very desirable materials in a range
of biomedical applications.1,2 CNT-mediated drug delivery has
generated special interest.1,3–11 By functionalising the outer
walls of the nanotubes via attaching target-specific molecules
(e.g. antibodies), drugs can be delivered to specific targets. IronAbbreviations: CNTs, carbon nanotubes; gC1q, globular head regions of
human C1q; MWNTs, multi walled CNTs; Fe-MWNTs, iron filled multi
walled CNTs; SWNTs, single-walled CNT; DWNTs, double-walled CNT.
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promise magnetic drug delivery and hyperthermia therapy. 3,12,13
Due to their hydrophobicity and length, making stable
dispersions of CNTs in physiological buffers, essential for
drug delivery, is a common obstacle. Thus, non-covalent and
covalent modifications of the CNT surfaces that include pre-
coating with proteins, surfactants, nucleic acids, or introducing
new functional groups on the external walls, are used. The
biocompatibility of CNTs can be significantly improved when
their surface is functionalized.1,14–16
Understanding the interactions between nanoparticles and
immune system would facilitate their strategic and specific
in vivo delivery.17 The innate immune system plays a key role in
protection against microorganisms and synthetic particles includ-
ing CNTs.18–21 Activation of the complement system, a major
component of the innate immunity,22 can influence therapeuticnanotubes and its influence on the phagocytosis and cytokine response by
16/j.nano.2014.02.010
Figure 1. Scanning electron microscopy images of pristine (A and B) and CMC-coated (C and D) Fe-MWNTs showing high purity of the pristine samples and
high dispersion of the functionalized samples. The dispersions are very stable (non-sedimenting).
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nanoparticles to adhere to immune cells. In addition, activation of
the complement system releases the bioactive peptides, C3a, C4a,
C5a, which contribute to inflammation.19–22
The complement system is composed of a group of N40
plasma and cell surface proteins,22 which recognises and clears
non-self (microorganisms) and altered self (apoptotic and
necrotic cells, aggregated proteins, etc.). It can be activated
via three pathways: classical, alternative or lectin, all of which
converge on the formation of a C3 convertase, a protease which
activates C3 that gets cleaved into C3b.23 The target-bound C3b
and a degradation product, iC3b are powerful opsonins, i.e. they
mediate binding of the target to phagocytic cells. In the classical
pathway, C1q binds to charged or hydrophobic clusters on
targets,23 via its globular (gC1q) domain, followed by
activation of two protease proenzymes, C1r and C1s, which,
with C1q, form the C1 complex. This is followed by cleavage of
C4 and C2, to form C4b2a, the C3 convertase. In the lectin
pathway, Mannose-Binding Lectin (MBL) and Ficolins recog-
nise neutral sugar and other uncharged features,24 and form
C4b2a via the MBL-associated serine proteases (MASPs). The
alternative pathway involves a constant but slow hydrolysis of
C3 in solution, which forms C3(H2O). It forms a complex with
Factor B, activated by Factor D (FD) to form C3(H2O)Bb (a C3
convertase).25 C3b, which binds randomly and covalently to
any nearby surface or particle, is stabilised by properdin, an
upregulator of the alternative pathway. This stage is followed
by generation of C5 convertase to cleave C5 to form C5a and
C5b. C5b binds to C6, C7, C8 and C9 to form the C5b-9
complex, or membrane attack complex (MAC), which can
insert into the lipid bilayer of the target and cause cell lysis.25
The small fragments, C3a, C4a and C5a, promote inflammationas anaphylactic or chemotactic factors. Once C3b is deposited
on a complement-activating particle, it is processed to form the
products, iC3b and C3dg/C3d. These complement fragments
are recognised by different complement receptors on various
cell types, and the receptor–ligand interaction can cause the
particle to adhere to the cell.22 The receptors involved include
Complement Receptor 1 (CR1) which binds C3b and C4b; CR2,
which binds C3dg/C3d, CR3; and CR4 which bind iC3b and
CRIg (C3b and iC3b).26
Non-functionalized SWNTs (single-walled) and DWNTs
(double-walled), when placed in contact with human serum,
activate complement via the classical and (to a lesser extent) the
alternative pathway.19 SWNTs, stabilised with several poly
(ethylene glycol) derivatives, show no alternative pathway
activation but C4 cleavage occurs, suggesting complement
activation via the lectin pathway.27,28 Functionalization (altering
the surface properties of the CNTs) can increase or decrease the
extent of complement activation,15,18,27,28 while differing surface
modifications can switch complement activation from one pathway
to another. The mode of binding of the recognition subcomponents
of the three pathways toCNTs, andwhether they bind directly or via
other deposited (serum) adaptor proteins, remains unclear. Accord-
ing to Ling et al, 29 C1q “crystallizes” on CNTs, but is not bound in
a way that allows activation of the next step of the complement
cascade. Thus, other serum proteins may form a stable layer on the
CNTs, triggering indirect C1 binding and complement activation.
Salvador-Morales et al,18,19 however, observed direct binding of
C1q to CNTs and subsequent complement activation.
In this study, we show several types of pristine and non-
covalently functionalized CNTs activate the complement sys-
tem predominantly via the classical pathway, which continues
up to the activation of C3 and C5, confirming the findings of
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leading to the formation of MAC. The interaction of C1q with
these CNTs appears to occur via the gC1q domain since the
recombinant forms of the gC1q regions of A, B and C chains
bind CNTs stably. The binding of globular heads takes place in an
orientation that inhibits the binding of serumC1q, thus suppressing
C1-mediated classical pathway activation. We also report that
complement activation and deposition on the surface of these
CNTs enhance their uptake by macrophages (U937 cell line) in a
time-dependent manner. Complement opsonisation of CNTs also
leads to modulation of pro-inflammatory and anti-inflammatory
cytokine expression by U937 cells and human monocytes.Figure 2. Complement activation via both the classical and alternative
pathway for coated Fe-MWNTs. Samples were incubated with human serum
for 1 h. Zymosan was used as the positive control. Zero complement
consumption was based on a negative control: serum incubated without
CNTs. Percentage complement consumption was calculated as (C − Ci)/
C × 100%, where C represents the total complement activity in CH50 units
of the negative control, Ci is the amount of activity remaining in the
supernatant of the sample tested. All experiments were done in triplicate;
error bars represent ± standard deviation.Methods
Carbon nanotube dispersions
Purified catalytic vapour deposition DWNTs and Fe-
MWNTs were prepared as described earlier.30,31 To remove
the iron filling (MWNTs), the samples were annealed under
Argon to 2500 °C.32 SWNTs were purchased from Nanocyl
(Sambreville, Belgium) and dispersed using non-covalent
functionalization via 2 min ultrasonication in PBS containing
various dispersants with 5 mM EDTA, pH 7.4. Proteins used for
dispersion were 4% w/v human fibrinogen (FBG) (Calbio-
chem), 4% w/v bovine serum albumin (BSA) (Sigma), and 4%
(w/v) human serum albumin (HSA) (Sigma). Other dispersants
used were 1% v/v Tween 20 (Sigma), 2% w/v Carboxymethyl
cellulose (CMC) (Sigma), 2% w/v phospholipid polyethylene
glycol (PL-PEG-NH2) (Avanti Polar Lipids) and 1% w/v
baker’s yeast RNA (Sigma). After sonication, the samples were
centrifuged at 8000 g for 5 min to remove aggregates and the
supernatants were washed by vacuum filtering using a 0.2 μm
polycarbonate filter (Whatman) with PBS–5 mM EDTA in
order to remove an excess of surfactants. Functionalized CNTs
were re-suspended in PBS–EDTA and analysed using a Zeiss
HR-LEO 1550 FEG Scanning Electron Microscope (SEM)
(Figure 1). Length and diameter distributions of the MWNTs were
determined from TEM images (data not shown); length 2.3±1.9
μm (n=562) diameter 23 ±11 nm (n=275).
Concentrations and extinction coefficients at 730 nm of all
CNTswere determined in triplicates using a gravimetric method.33
Briefly, CNTs were functionalized using RNA as described above,
and after washing, absorption at 730 and 808 nmwas measured for
a series of dilutions. The solution was incubated with RNAse (1
mg/mL) (Sigma) at 37 °C for 3 h. After extensive washing, CNTs
were dried on aWhatman 0.2 μm filter. The extinction coefficients
found were used to determine the concentrations of the other
functionalized CNT samples.
Opsonization of CNTs with C1q, ghA, ghB and ghC proteins
C1q was purified from human plasma using affinity
chromatography on IgG-Sepharose.34 The C-terminal globular
regions of human C1q A, B and C chains, designated ghA, ghB
and ghC, were expressed as maltose-binding-protein fusion
proteins in E. coli.35 CMC-MWNTs were incubated with C1q,
ghA, ghB or ghC, separately or mixed together, at 1:2 w/w ratiosin 50 mM Tris, 100 mM NaCl, 5 mM CaCl2, pH 7.5 overnight at
4 °C. Excess proteins were removed by washing three times in
the same buffer. Protein binding was analysed by SDS-PAGE.
Complement activation and consumption assays for the
classical pathway
To investigate whether CNTs activated (consumed) comple-
ment in human serum19, CNTswere incubated with normal human
serum (SeraLab) for 1h at 37 °C, removed by centrifugation, and
the capacity of the incubated serum to lyse antibody-sensitised
sheep erythrocytes (EA) was tested. EA were prepared19 using
sheep erythrocytes from TCS Biosciences and stored in dextrose
gelatin veronal buffer (DGVB++: 2.5 mM sodium barbital, 71 mM
NaCl, 0.15 mM CaCl2, 0.5 mMMgCl2, 2.5% w/v glucose, 0.1%
w/v gelatin, pH 7.4) at 109 cells/ml concentration.
CNT suspensions (100 μl of 0.1 mg/ml) in PBS were added to
100 μl of 1:1 diluted human serum in DGVB++. Zymosan (0.2 mg
in 100 μl PBS; Sigma) served as a positive control. Samples were
incubated with occasional shaking at 37 °C for 1 h followed by
centrifugation (13,000 g, 10min). The supernatants of each sample
were serially double-diluted (1/10 to 1/5120 in DGVB++) and
placed in microtitre wells. 100 μl of each dilution was incubated
with 100 μl of EA (108 cells/ml) in DGVB++ in U-shaped wells
(Fisher Scientific) for 1 h at 37 °C. Next, cells were spun down
(700 g, 10 min, RT), and released haemoglobin in the supernatant
was read at 405 nm. Total haemolysis (100%) was measured by
lysing EA with water. Background spontaneous haemolysis (0%)
was determined by incubating EA with buffer only. CH50 values,
which correspond to the dilution factor of the serum that results in
50% cell lysis, were calculated and compared.
To investigate whether coating CNTs with C1q or ghA, ghB
and ghC modified the activation of complement in human
serum induced by CNTs, complement consumption assay was
Figure 3. Complement consumption for total complement (classical pathway assay) and C3 and C5 consumption for DWNTs- pristine as well as coated with
various plasma proteins (BSA, HSA, FBG) or Tween 20. DWNTs were pre-coated as described in Methods and incubated with human serum for 1 h. Zymosan
samples were used as the positive control. Zero complement consumption was based on a negative control: serum incubated without CNTs. Percentage of
complement consumption was calculated as (C − Ci)/C × 100%, where C represents the total complement activity in CH50 units of the negative control, Ci is
the amount of activity remaining in the supernatant of the sample tested. All experiments were done in triplicate; error bars represent ± standard deviation.
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CMC-MWNTs at 100 μg/ml in 50 mM Tris, 150 mM NaCl, and
5 mM CaCl2 pH 7.5 buffer were incubated at 37 °C for 1 h with
equal volumes of 1:1 diluted serum in DGVB++ to give a total
volume of 50 μl followed by centrifugation (13,000 g, 10 min),
supernatants were collected and assayed.
Complement activation and consumption assay for the
alternative pathway
EAIgG cells were made by treating SRBCs with the IgG
fraction of rabbit anti-SRBC antibodies (GE Healthcare). EAIgG
cells were diluted to 109 cells/ml in DGVB-Mg-EGTA (2.5 mM
sodium barbital, 71 mM NaCl, 7 mM MgCl2, 10 mM EGTA,
2.5% w/v glucose, 0.1% w/v gelatin, pH 7.4).
Nanotube suspensions (100 μl of 0.1 mg/ml in PBS) were
added to 100 μl undiluted human serum and incubated for 1 h at
37 °C. Zymosan (0.2 mg) served as a positive control. The
supernatants of each sample were serially diluted (1/5 to 1/320 in
DGVB-Mg-EGTA) and placed in microtitre wells. 100 μl of
each dilution was incubated with 100 μl of EAIgG (10
9 cells/ml
in DGVB-Mg-EGTA) for 1 h at 37 °C. Further steps were
performed as above.
C3 and C5 consumption assay
To analyse whether the complement activation by CNTs
continued up to the activation of C3 and C5, an adapted
haemolytic assay was performed. 20 μl of serum diluted 1/20 in
DGVB++ was incubated for 1 h at 37 °C with or without CNTs
(20 μL 0.1 mg/mL in PBS) and the nanotubes were removed by
centrifugation. Then, 20 μl of the supernatant added to 20 μl 1/20
diluted C3-depleted serum (Sigma) or C5 depleted serum
(Quidel) and 100 μl EA cells at 108 cells/ml in DGVB++ and
incubated for 1 h at 37 °C. Further procedures and thecalculation of the activity (titre) of C3 or C5 were done as
described above.Phagocytosis assay
To biotinylated carbon nanotubes, MWNTs functionalized
with CMC were washed thoroughly to remove excess CMC.
CMC-CNTs were dialysed against 0.1 M MES buffer (2-(N-
morpholino)ethanesulfonic acid, pH 5) and made to 0.2 mg/ml.
Pentylamine biotin (Pierce) (10 mg) was added to 10 ml of the
CMC-CNTs at 0.2 mg/ml and 100 μl of a 20 mg/ml solution of
EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) in 0.1
M MES buffer pH 5 was added. The reaction (Supplementary
information S1) was allowed to take place for 2 h at RT with
stirring, and was stopped by adding 100 μl of 0.1 M
ethanolamine, pH 8.2. The resulting biotin-CMC-CNTs were
dialysed into PBS (pH 7.4) to remove remaining reactants and
MES.
U937 cells (a monocytic cell line derived from histiocytic
lymphoma) were cultured in complete RPMI 1640 containing
10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin and 1 mM sodium pyruvate, and
passaged before use. In each well of a 24 well plate, 5 × 105 cells
were incubated in complete RPMI 1640 or AIM-V AlbuMAX
serum free medium (GIBCO) supplemented with glutamine,
pyruvate penicillin and streptomycin as above. 20 μg of biotin-
CMC-CNTs in 20 μl PBS was added to each well and incubated
for 15, 30, 45, 60, 120 or 360 min. Cells were harvested and
washed five times in PBS using centrifugation at 300 g and
stored at −80 °C until further use. A test with the same washing
and Sepharose beads (instead of cells) with biotin-CMC-CNT
dispersion showed that suspended CNTs remained in dispersion
and were washed away by this method. The supernatants were
removed and 25 μl lysis buffer (10 mM HEPES, 20 mM NaCl,
0.5 mM EDTA, 1% w/v Triton X 100) was added to the cells.
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added to the dispersion to use in the quantification assay. The
IgG was added as a blocking agent to minimise non-specific
binding reactions.
An ELISA type assay was developed to quantify the amount
of CNTs taken up by cells (see Supplementary material S2).
Microtitre wells (NUNC, polysorb) were coated with 100 μl
Avidin (Pierce) at 50 μg/ml in 0.1 MNa2CO3, pH 9 for 1 h at RT,
followed by blocking with 1 mg/ml horse IgG in PBS for 1 h at
RT. Next, 50 μl of a solution or cell lysate containing biotin-
CMC-CNTs and 50 μl of 0.1 mg/ml horse IgG was incubated for1 h in each well. The plate was washed 7 times with 0.1 mg/ml
IgG in PBS to remove excess CNTs and then incubated with
1:2000 dilution of Streptavidin-HRP (Sigma) for 1 h at RT.
Following washing again, O-Phenylenediamine dihydrochloride
(OPD) (Sigma) was used as a substrate for the HRP and the
yellow 2, 3-Diaminophenazine product was read at 450 nm.Measurement of cytokine mRNA expression using quantitative
PCR analysis
In a 24well cell culture plate, 20 μg of CMC-MWNTs or RNA-
MWNTs in 20 μl PBS was added to each well containing 5 × 105
U937 cells and incubated for 15, 30, 45, 60, 120 or 360 min;
control samples were incubated with PBS only for 30 min. Cells
were harvested, spun down (3000 g, 5 min), and stored at −80 °C.
Total RNA was extracted from frozen cell pellets using the
GenElute Mammalian Total RNA Purification Kit (Sigma-
Aldrich). Samples were treated with DNase I to remove any
contaminating DNA. To inactivate both DNase I and RNase,
samples were heated at 70 °C for 10min, and subsequently chilled
on ice. The amount of total RNA was determined at 260 nm using
the NanoDrop 2000/2000c (Thermo-Fisher Scientific), and the
purity was assessed using the ratio of absorbance at 260 nm and
280 nm. cDNA was synthesized using High Capacity RNA to
cDNA Kit (Applied Biosystems) using 2 μg of total RNA extract.
Primer sequences were designed and analysed for specificity
using the nucleotide BLAST and Primer-BLAST (http://blast.
ncbi.nlm.nih.gov/Blast.cgi). The following primers were used:
18S forward (5’-ATGGCCGTTCTTAGTTGGTG-3’), 18S
reverse (5’-CGCTGAGCCAGTCAGTGTAG-3’), IL-1β for-
ward (5’-GGACAAGCTGAGGAAGATGC-3’), IL-1β reverse
(5’-TCGTTATCCCATGTGTCGAA-3’), IL-6 forward (5’-GAAA-
GCAGCAAAGAGGCACT-3’), IL-6 reverse (5’-TTTCACCAGG-
CAAGTCTCCT-3’), IL-10 forward (5’-TTACCTGGAGGAGG-
TGATGC-3’), IL-10 reverse (5’-GGCCTTGCTCTTGTTTTCAC-3’),
IL-12 forward (5’-AACTTGCAGCTGAAGCCATT-3’), IL-12
reverse (5’-GACCTGAACGCAGAATGTCA-3’), TGF-β forwardFigure 4. (A) Binding of C1q onto CMC-CNTs. Samples of CMC-MWNTs
incubated with purified C1q and washed extensively were analysed by SDS-
PAGE (8%) in reduced conditions. Lane 1: Molecular weight marker; lane 2:
C1q coated CMC-MWNTs; lane 3: CMC-MWNTs. The bands visible are
C1q A and B chains (~25 kDa) running above the C chain (~22 kDa).
(B) Binding of ghA, ghB and ghC onto CMC-CNTs. Samples of CMC-
MWNTs incubated with recombinant ghA, ghB or ghC and washed extensively
were analysed by SDS-PAGE (12%) under reduced conditions. Lane 1:
Molecularweightmarker; lane 2: ghA coatedCMC-MWNTs; lane 3: ghB coated
CMC-MWNTs; lane 4: ghC coated CMC-MWNTs. The bands seen at about 65
kDa are fusion proteins formed from C1q globular heads a, b, or c, and maltose
binding protein. (C) Complement inhibition assay to show that pre-coating of
CNTswith ghA, ghB, ghCor an equimolarmixture of three recombinant proteins
inhibits complement activation. CNTs were coated with the proteins in a ratio of
1:2 w/w, by incubating the CNTs with proteins overnight and washed. Samples
were incubated with human serum for 1 h. Zero complement consumption was
based on a negative control: Serum incubated without CNTs. Percentage of
complement consumption was calculated as (C − Ci)/C × 100%, where C
represents the total complement activity in CH50 units of the negative control, Ci
is the amount of activity remaining in the supernatant of the sample tested.
Zymosan was used as positive control. All experiments were done in duplicate;
error bars represent ± standard deviation.
Figure 5. Uptake of CNTs by U937 cells in the presence and absence of
serum. U937 cells were incubated with biotinylated CMC-MWNTs for 15,
30, 45, 60, 120 and 360 min. Excess CNTs were washed away and cells were
lysed. The amount of CNTs in the lysate was quantified using a newly
developed assay (supporting information S2). A standard curve with known
concentrations of biotin-CNTs was performed in the same assay to calculate
the mass of the CNTs in the cell samples. All experiments were done in
triplicate; error bars represent ± standard deviation.
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GTATCGCCAGGAATTGTTGC-3’), TNF-α forward (5’-AGCC-
CATGTTGTAGCAAACC-3’) and TNF-α reverse (5’-TGAGG-
TACAGGCCCTCTGAT-3’).
The qPCR reaction consisted of 5 μl Power SYBR Green
MasterMix (Applied Biosystems), 75 nM of forward and reverse
primers and 500 ng template cDNA in a 10 μl final reaction
volume. PCR was performed in a 7900HT Fast Real-Time PCR
System (Applied Biosystems). The initiation steps involved
2 min at 50 °C followed by 10 min at 95 °C. The template was
then amplified for 40 cycles, each cycle comprised of 15 s at
95 °C and 1 min at 60 °C. Samples were normalized using the
expression of human 18S rRNA. Data were analyzed using the
RQ Manager Version 1.2.1 (Applied Biosystems). Ct (cycle
threshold) values for each cytokine target gene were calculated
and the relative expression of each cytokine target gene was
calculated using the Relative Quantification (RQ) value, using
the equation: RQ = 2−ΔΔCt for each cytokine target gene, and
comparing relative expression with that of the 18S rRNA
constitutive gene product. Assays were conducted in triplicate.
Complement dependent interactions of CNTs with human
monocytes and measurement of cytokine mRNA expression
Human monocytes were isolated from fresh blood from a
healthy consenting individual using a Ficol-Paque plus (GEFigure 6. In vitro mRNA expression of cytokines by (A) U937cells incubated wit
monocytes incubated with CMC-CNTs. U937 cells were incubated with CMC-MW
120 and 360 min. Monocytes were incubated with CMC-MWNTs for 15, 30, 45 a
The mRNA expression of cytokines was measured using real time qPCR and the d
(RQ) was calculated by using the comparative Ct method with cells incubated w
calculated using the formula: RQ = 2−ΔΔCt. Assays were conducted in triplicate.
t test was performed on the data and significant differences in expression at a g
follows: All time points showed significant differences in expression, P≤0.01, ex
monocytes, a 2-way ANOVA was performed on the data and significant differen
samples and serum and heat-inactivated serum are shown as follows: All time poi
shown significant, *: 0.01 b P b 0.05, and **:P≤0.01.Healthcare) gradient according to the manufacturer’s instruc-
tions. Lymphocytes and monocytes (PBMCs) obtained from the
interface of plasma and Ficol-Paque were washed twice in RPMI
1640 and suspended in RPMI 1640. 2.5 × 106 PBMCs were
plated out in each well of a 12 well plate (SPL Life Sciences),
pre-coated with human serum overnight. After 2 h of incubation
at 37 °C in 5% CO2, the non-adherent PBMCs were gently
removed away from adherent monocytes.
Medium was replaced by complete RPMI 1640 (containing
10% human serum), or complete RPMI 1640 containing 10% heat
inactivated human serum (30 min 56 °C) or AIM-V AlbuMAX
serum free medium (GIBCO) with 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin and 1 mM
sodium pyruvate. 10 μg CMC-MWNTs in PBS was added to
each well and incubated for 15, 30, 45 or 60 min, control
samples were incubated with PBS only for 30 min. Cells
were harvested and spun down (3000 g, 5 min) and stored at
−80 °C. Further treatment and preparations were similar to
as described above.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 6.0 (GraphPad Software). For the experiments with
U937 cells, an unpaired 2-side t test was used to compare the
means of the cytokine targets with and without serum for any
significant difference in expression. P values were computed,
graphs compiled and analysed.
A 2-way ANOVA test was performed on the data obtained
from the monocyte experiments and significant differences in
expression at a given time point between serum and no
serum-treated samples; and serum and heat-inactivated serum
were determined.Results
Complement (classical and alternative) is activated by various
forms of CNTs
The activation of the classical and alternative pathway by Fe-
MWNTs coated with CMC, RNA and PL-PEG-NH2 is shown in
Figure 2. All the CNT samples tested activated complement
through both pathways, but predominantly through the classical
pathway. C3 and C5 consumption analysis showed that
complement activation continued up to C5, indicating formation
of MAC (Figure 3). Differences in complement activation mighth CMC-CNTs. (B) U937 cells incubated with RNA-MWNTs. (C) Adherent
NTs or RNA-MWNTs in the presence or absence of serum for 15, 30, 45, 60,
nd 60 min in the presence of serum, heat inactivated serum, or without serum.
ata normalised to 18S rRNA gene expression as a control. Relative expression
ith PBS for 30 min as the calibrator (data not shown). The RQ value was
Error bars represent ± standard error of the mean. For U937 cells, a two-side
iven time point between serum and no serum-treated samples are shown as
cept where shown significant, *: 0.01 b P b 0.05, and ns: not significant. For
ces in expression at a given time point between serum and no serum-treated
nts showed non-significant differences in expression, P≥0.01, except where
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chemical nature of the coating substance.
C1q binds to CNTs via its gC1q domain
The binding of C1q was analysed by incubating CMC-
MWNTs with individual C1q globular heads. All globular heads
were shown to bind to the CNTs (Figure 4, A, B), indicating the
orientation of C1q on the CNTs with the head regions onto the
CNTs. This binding is most likely through charge pattern
recognition. In this orientation, binding of C1r and C1rs is
possible, and therefore, complement activation via the classical
pathway is initiated. Coating MWNTs with globular heads
showed very effective inhibition of complement activation
(Figure 4, C). This opens up a way to reduce the recognition
of the particles by the innate immune system.
Complement dependent interactions of CNTs with U937 cells
and monocytes, phagocytosis and cytokine expression
CNTs were incubated with U937 cells in the presence and
absence of serum, either allowing complement activation to
occur or not, and monitored for phagocytosis through a newly
developed assay for up to 6 h. The efficiency of phagocytosis of
CNTs by U937 cells is enhanced by the presence of serum,
strongly suggesting that complement proteins may be involved
in this process (Figure 5). In order to examine the pro- and anti-
inflammatory responses during this interaction, 6 key cytokines
were analyzed for their expression during the course of
phagocytosis (Figure 6). The data show that all cytokine
responses studied are dampened in the presence of serum. The
immune responses also showed similar expression patterns when
compared between two types of CNTs. For the RNA-CNT
without serum, cytokine responses have a biphasic pattern with a
sharp upregulation in the first 15 min. of phagocytosis, which
diminishes and then peaks again at 45 min. (Figure 6, B). IL-10
is also downregulated in the early stages of phagocytosis, but is
slowly upregulated between 60 min. and 360 min. A similar
pattern is also observed in IL-12, IL-6 and IL-1β, although the
effect seems more subtle in nature. For the CMC-CNT, similar
patterns of cytokine expression to those seen with RNA-CNT
were observed, although it does not appear to be biphasic in
nature (Figure 6, A). The initial upregulation appears to be
longer in duration (during the first 30 min.), but then seems to
diminish and plateau and be slightly downregulated.
In all six cytokines studied for the RNA-CNTs, there is on
average a log two-fold difference in expression between serum-
treated versus untreated during the first 15 min. of phagocytosis.
In the presence of serum, cytokine expression is always
downregulated, and this is particularly notable in IL-12 where
a log two-fold down regulation is observed. The differences in
cytokine expression observed for CMC-CNTs are similar,
although the average fold difference between expression in
serum treated versus no serum during the first 15 min of
phagocytosis was less, at about log one-fold difference. IL-10 is
downregulated in the presence of serum quite markedly during
the early stages of phagocytosis with a log two-fold difference
between serum and no serum.To further validate the results obtained using CNTs and U937
cells, freshly isolated monocytes were incubated with CMC-
CNTs with and without normal human serum, as well as heat-
inactivated serum. Heat inactivated serum yielded results
comparable with serum free conditions, suggesting that down-
regulation of pro-inflammatory cytokines by serum results from
complement deposition on the CNTs. This effect was most
evident for TNF-α and IL-1β, and also for TGF-β, IL-12 and IL-
6 in the late phase.Discussion
The precise inflammatory properties of CNTs are still being
examined but various studies suffer from inconsistent findings.
The type of functionalization on the surface of CNTs appears to
be one of the key factors in modulating these inflammatory
properties.36 Host serum proteins can also enhance and/or mask
the physiochemical characteristics of these CNTs. CNT in-
teractions with complement proteins clearly play a key role in
inflammation.
The rationale for the predominant classical pathway activa-
tion by CNTs remains an area of investigation. It is established
that C1q binds to CNTs 29 but a recent study has reported that
CNT-bound C1q fails to activate complement due to the lack of
C1 assembly.28 C1q binds generally by ionic interactions with
rearrangement to stronger hydrophobic interaction.37 C1q is a
charge pattern recognition molecule.38,39 It is likely that
derivatisation of CNTs creates diverse C1q-recognisable molec-
ular patterns. Thus, C1q binds these modified CNTs via its gC1q
domain as indicated by binding of the recombinant ghA, ghB and
ghC, which are able to inhibit classical pathway activation. Thus,
in the case of CMC-CNTs, C1q binds via the gC1q domain in an
orientation that supports complement activation. It is possible
that under certain circumstances, C1q adaptor molecules such as
IgG, IgM, CRP, SAP and PTX3 can first bind to CNTs, thus,
allowingC1q to dock and then trigger classical pathway activation.
However, the classical pathway complement inhibition caused by
direct coating of CNTs with recombinant ghA, ghB and ghC
appears to suggest a direct interaction between C1q and the CNTs.
C1q binding alone does not guarantee that the whole
complement system is activated, or that the nanotube becomes
coated with C3b. In order to activate the whole complement
system, pristine or surface-modified CNTs need surface features
which allow binding of C4 and C3. If, for example, a surface
binds and activates C1, then C4 is activated, but if there is no site
to which C4b can bind, C4b2a will not form efficiently and there
will be very limited turnover of C3.40 If C4b2a forms on the
surface, either by hydrophobic absorption or by covalent
attachment of C4b to OH, NH2 or SH groups, C3 will be
activated (consumed). The C5 convertase C4b2a3b will be
formed, if C4b2a is accessible on the surface to bind C3b. If C3b
can bind appropriately, C5 will be activated (consumed). Each
complement pathway ends in the formation of the C5-9 complex
or MAC. A rise in MAC levels after interaction between
PEGylated SWNTs and human serum has been reported,
indicating that complement activation proceeds through the
entire complement cascade,27 and further work by Andersen
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complete complement cascade is activated. This is important in
understanding the capacity of nanomaterials to generate
anaphylatoxins such as complement fragments C4a, C3a and
C5a. In our study, we confirm that complement is activated until
the consumption of C3 and C5 for both pristine and derivatised
CNTs. Consumption of C5 is a clear indicator of formation of
MAC. Since C3 and C5 consumption is substantial, C3 and C5
convertases must form on the CNT surface. This, in turn, means
that there are binding sites for C4b and C3b. Formation of
complement fragments C3a, C4a and C5a promote inflamma-
tion, and depending on dose and route of administration, may
cause problems when CNTs are used as drug delivery agents.41
As noted above, C3b and C4b can bind covalently to surface
nucleophilic groups, such as OH, NH2. These will be of very low
abundance on the pristine CNT surface, but possibly adsorbed
dispersant, protein or HDL19 provides such sites. SDS-PAGE
and Western blotting analysis of C3 fragments bound to CNTs
(data not included) suggested that C3b does not form covalent
adducts with higher molecular weight species (proteins) when
bound to the CNT. It may bind covalently to molecules such as
unesterified cholesterol (in adsorbed HDL),42 or it may bind via
hydrophobic interactions possibly directly to the CNT surface.
An important role of protein adsorbed on the CNT surface in
uptake by phagocytic cells has been noted.43 CNTs have been
shown to be engulfed by phagocytic cells via a range of
phagocytic and endocytic mechanisms.14 The phagocytosis data
here are consistent with the known role complement plays in
facilitating microbial uptake by macrophages. Thus, serum
opsonisation or complement deposition enhanced uptake of
labelled CNTs almost by two-fold at the time points tested.
Curiously, the quantity of intracellular serum-treated CNTs
continued to increase post 60 min. whereas the level of non-
opsonised CNTs started to diminish. It will be interesting to track
the intracellular route of opsonised and non-opsonised CNTs in
order to understand their fate following uptake. Complement or
serum protein deposition likely renders CNTs resistant to
phagolysosomal degradation of their coating, with possible
loss of biotin label. Alternatively, untreated CNTs could
potentially be transcytosed by the cells, being recognised as
biologically irrelevant debris. Studies to delineate various
aspects of cytoplasmic trafficking of CNTs are under way.
Reports suggest that CNTs stay in the cytoplasm either free or in
endosomes,8,44 while others state that the CNTs also enter the
cell nucleus.45–47 Exocytosis has not been reported often and the
time course for the process varies between simultaneous with
endocytosis48 until after 5 h of incubation.44
MWCNTs have been shown to stimulate secretion of pro-
inflammatory cytokines such as IL-1β, TNF-α, IL-8 and IL-
6.49,50 CNTs induce an acute and robust inflammatory response
in mice51 as well as by human monocytes in vitro.52 Here, we
report that CMC-CNTs alone induced upregulation of IL-10,
TNF-α and IL-1β within 30 min. of the exposure to U937 cells;
most of these responses were dampened in the presence of
serum/complement deposition. In the case of RNA-CNTs, IL-10
was weakly upregulated by the opsonisation, which may raise
the antigen threshold for an adaptive immune response. The
biphasic TNF-α and IL-1β response induced by RNA-CNTs wasseriously dampened by serum treatment. Serum also appears to
have dampened IL-12 production by U937 cells. It appears that
complement deposition may sequester CNT-mediated pro-
inflammatory response towards an anti-inflammatory environ-
ment. Further studies are required to understand roles of specific
complement proteins in modulating phagocytic and immune
properties of macrophages. It also indicates that complement
may facilitate the dampening of inflammation during this
phagocytic process, resulting in more efficient cell recruitment.
The importance of complement activation and deposition was
further analysed by heat inactivation of the serum in the
experiments with monocytes. Under these conditions cytokine
profiles were similar for heat inactivated and serum free conditions.
These observations have particular importance in targeted
tissues and cells, where the use of CNTs in therapy may lead to
tissue damage as a result of inflammation. The presence of
complement proteins as opsonins for CNTs or the coating of
tissues by these proteins, will facilitate a reduction in any
possible tissue damage as a result of an exaggerated inflamma-
tory response to the CNTs. It is therefore important to further
elucidate the precise immunological signature of these functio-
nalized CNTs, not only to predict their use as a therapeutic
vehicle, but also to gain insights into any unwanted pathologies
or toxicity, particularly on targeted tissues and cells. The data and
assays presented here, may serve as important screens for new
functionalized CNTs before they are tested for in vivo studies.
CNTs are not biodegradable and are unlikely to be used for
multiple-dose administration, but they could be used in prostheses,
or in single dose treatments and with the increase of use of CNTs
the risk of accidental exposure increases. Studies on complement
activation by carbon nanotubes are useful as models for other
(carbon-based) nanomaterials as well as for toxicology.
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